Cart
0
Get 20% Free Customization In This Report
Buy this report from - $4176

Biosimilars Market (Follow-on-Biologics) by Types (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Peptide) and Application (Blood disorders, Oncology diseases, Growth hormone deficiencies) - Global Opportunity Analysis and Industry Forecast, 2014-2020

LI_15700
Pages: 120
Sep 2015 | 8570 Views
face gplus_n
Author's : Vivek Singh
Tables: 40
Charts: 37
twit_n pr_n

Biosimilars Market Overview :

Global biosimilars/follow-on-biologics market was valued at $2,552.0 million in 2014 and is expected to reach $26,551.3 million by 2020, supported by a CAGR of 49.1% during the forecast period 2015 to 2020. Biosimilars or follow-on-biologics are the “copied” and licensed versions of those reference biologics that have undergone patent expiration. Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. Regulations for biosimilars play a vital role in maintaining the viability and balance between original and biosimilars products. Various regulatory authorities such as EMA and FDA actively regulate the biosimilars commercialization and development.

The market is driven by factors such rising prevalence of chronic diseases such as cancer and diabetes supplement the growing demands of pharmaceutical drugs, especially for the high priced patented drugs. However, the market growth is limited by the high cost of reference products increases the financial burden on patients as well as reimbursement service providers. The lack in economies of scale due to lower demand is a factor that results in these high costs. Furthermore, the growth of the biosimilars market is hampered due to the lack of regulatory guidelines, consumers brand preferences, reluctance of physicians to prescribed biosimilars and the high capital required for research and development. Countries from the European Union presently dominate the market owing to the favorable government regulations in this region. North America biosimilars market is currently witnessing restrictions due to the flexible and ineffective regulations.

Biosimilars Market Segmentation

Biosimilars Market Segmentation

Get more information on this report : Request Sample Pages

Segment review

The product segment in the biosimilars market comprises of Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Colony Stimulating Factors and others. The biosimilars applications market is segmented into blood disorders, oncology diseases, chronic and autoimmune diseases and growth hormone deficiency. The application of biosimilars in blood disease treatment is the highest revenue generating segment owing to the high-priced reference biologics and frequent application.

However, biosimilars applications in autoimmune and chronic diseases exhibit the highest potential due to the changing off patent scenario. Biopharmaceutical industry is vastly dependent on the advanced technologies used in various procedures of development and manufacturing. These technologies are acting as a mandate for every single operation in biopharmaceutical and healthcare research industry. Some of the significant technologies are discussed in the report includes, Monoclonal Antibodies (MAb) Technology, Recombinant DNA Technology (rDNA technology), Nuclear magnetic resonance (NMR) technology, Chromatography, Electrophoresis, Mass Spectrometry, Western Blotting and Bioassay. Monoclonal antibody technology and bioassay technologies are the most significant technologies used in biosimilar development and validation. Based on geography, the biosimilars market is segmented across North America, Europe, Asia-Pacific and LAMEA. Asia Pacific and LAMEA exhibit a large scale demand for biosimilars due to the growing prevalence of chronic diseases in these regions

Top Winning Strategies

Biosimilars Market Top Winning Strategies

Get more information on this report : Request Sample Pages

Manufacturers are the most important stakeholders for the biosimilars; pharmaceutical companies are largely focusing on the development of novel pharmaceuticals, especially for the blockbuster drugs. However, patent protections and availability of other intellectual rights are protecting these formulations from imitation. In such scenario, the pharmaceutical companies are shifting their focus over the development of biosimilars and for that these companies are adopting approval and clinical trials strategies.

Approval and clinical trials stand as principal strategy for the biosimilars market. The companies such as Sandoz, Merck Serono, and Celltrion are continuously seeking approvals across different geographies. These companies are subsidiaries of global companies such as Merck and Novartis, which enable them to invest into the biosimilar studies. Clinical trials and investments in product development are equally important as approvals. The strategies adopted by the companies are in integrated manner where clinical trials conducted for commercialization and approvals. Approval strategies accounted for 28.6% of overall strategies; while, clinical trials accounted 32.1%. Other strategies are currently following these strategies, as these strategies are the platform strategies for the others. License, partnership, product launch, joint venture, and co-development are some of the other strategies adopted by the companies who had received approval from the authorities and have successfully imitated the original biologics.

Top Investment Pockets

Biosimilars Market Top Investment Pockets

Get more information on this report : Request Sample Pages

The Global biosimilars products market is segmented into Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, G-CSF, peptide and other biosimilars. Patent expiration is a key factor that largely influences the biosimilars market. Most of the blockbuster patents would expire by the end of 2014; a factor that would provide competitive advantage to local pharmaceutical manufacturers over global players.

Most of the lucrative products in biosimilars industries are monoclonal antibodies, G-CSF erythropoietin and peptide. These products are currently commanding the biosimilars market and have received approval for commercialization in many geographies. Companies manufacturing these biosimilars are achieving economies of scale in the market; thus, receiving cost advantage in a price sensitive market. Further advancement in technologies would lead to the development of more competent biosimilars, such as Insulin and these biosimilars would outperform the existing biosimilars. `The companies that launched biosimilars in 2011 are generating high revenues by providing low cost biosimilar products. Growing awareness and low cost are the factors driving the market growth for monoclonal antibodies and human growth hormone biosimilars in current market.

This report provides a comprehensive market share analysis of leading companies and highlights the competition in the market. Product launch is the key strategy adopted by the leading player of biosimilars industry. The key companies profiled in this report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group).

Biosimilars/follow-on-biologics Market Key Benefits

  • This report provides a detailed analysis of drivers and factors that limit the market expansion.
  • The report provides market forecast for the next eight years by considering the 2014 as the base year for evaluation.
  • Comprehensive and quantitative data about changing market trends, competition and opportunities in biosimilars market are provided in the report.
  • Porters Five Forces model and SWOT analysis would help stakeholders in making strategic decisions.
  • Deep dive analysis of leading market players and their key strategies, helps in better understanding the market dynamics.
  • Identification of key investment pockets in the biosimilars market would help the stakeholders in making informed decisions.

Biosimilars Market Key Segments

By Types

  • Human growth hormone
  • Erythropoietin
  • Monoclonal antibodies
  • Insulin
  • Interferon
  • Granulocyte-Colony Stimulating Factor
  • Others

By Applications

  • Blood disorders
  • Oncology diseases
  • Chronic and autoimmune diseases
  • Growth hormone deficiencies
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
 

Chapter: 1 INTRODUCTION

1.1 Key Benefits
1.2 Key Market Segment
1.3 Research Methodology

1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond: what to expect by 2025

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

Chapter: 3 MARKET OVERVIEW

3.1 Market Definition
3.2 Diverse approach of global regulators towards biosimilars
3.3 Safety issues of biosimilar drugs
3.4 Key Findings

3.4.1 Top impacting factors
3.4.2 Top winning strategies
3.4.3 Top investment pockets

3.5 Regulation and Reimbursement scenario

3.5.1 Regulations in United States
3.5.2 Regulations in Europe
3.5.3 Regulation in Asia
3.5.4 Comparison of Biosimilar medicine guidelines

3.6 Emerging economies a hotspot for biosimilars market

3.6.1 Brazil a treasure for the biosimilar manufacturers
3.6.2 China the bulkmarket for biosimilars
3.6.3 India an early adopter of biosimilars

3.7 Porters five force analysis

3.7.1 Higher bargaining of suppliers
3.7.2 Moderate bargaining power of buyers
3.7.3 Higher threats from substitutes due to lower switching cost
3.7.4 Lower threats from new entrants due to technological and political barriers
3.7.5 Higher competition among players

3.8 Value chain analysis

3.8.1 Primary activities
3.8.2 Supportive activities

3.9 Clinical trials

3.9.1 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
3.9.2 Efficacy Study of Two Formulations of Erythropoietin
3.9.3 Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology
3.9.4 An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1

3.10 Market Share analysis, 2014
3.11 Market Dynamics

3.11.1 Drivers

3.11.1.1 Growing pressure to reduce healthcare expenditure
3.11.1.2 Various blockbusters going off patent
3.11.1.3 High prevalence of chronic diseases among ageing population
3.11.1.4 Favorable intervention from the developing economies
3.11.1.5 Lower cost biosimilars drugs than original biologics

3.11.2 Restraints

3.11.2.1 High initial investment in research and development
3.11.2.2 Stringent regulations in developed economies to restrict investment
3.11.2.3 Medical Efficacy and Patient Safety

3.11.3 Opportunities

3.11.3.1 opportunities in Emerging economies
3.11.3.2 Emergence of bio-betters drugs

Chapter: 4 GLOBAL MARKET BY TECHNOLOGY

4.1 Monoclonal Antibodies (MAb) Technology

4.1.1 Drivers

4.2 Recombinant DNA Technology (rDNA technology)

4.2.1 Drivers
4.2.2 Restraints & Opportunities

4.3 Chromatography

4.3.1 Protein sequencing
4.3.2 Liquid chromatography (LC)
4.3.3 Gas Chromatography (GC)
4.3.4 Drivers

4.4 Nuclear magnetic resonance (NMR) technology

4.4.1 Drivers

4.5 Electrophoresis

4.5.1 Drivers
4.5.2 Restraints & Opportunities
4.5.3 Gel Electrophoresis
4.5.4 Capillary Electrophoresis

4.6 MASS SPECTROMETRY

4.6.1 Drivers
4.6.2 Restraints

4.7 Western Blotting

4.7.1 Drivers

4.8 Bioassay

4.8.1 Drivers
4.8.2 Restraints
4.8.3 Techniques in Bioassay

Chapter: 5 GLOBAL BIOSIMILARS MARKET BY PRODUCT

5.1 Human Growth Hormone

5.1.1 Key market trends
5.1.2 Key growth factors and opportunities
5.1.3 Market size & forecast

5.2 Insulin

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size & forecast

5.3 Interferon

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size & forecast

5.4 Granulocyte colony stimulating factor (G-CSF)

5.4.1 Key market trends
5.4.2 Key growth factors and opporunities
5.4.3 Market size & forecast

5.5 Erythropoietin

5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size & forecast

5.6 Monoclonal antibodies

5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size & forecast

5.7 Peptides
5.8 Others

5.8.1 Key market trends
5.8.2 Key growth factors and opportunity

Chapter: 6 GLOBAL MARKET BY APPLICATIONS

6.1 Blood disorders

6.1.1 Drivers
6.1.2 Chemotherapy induce Anaemia

6.1.2.1 Drivers
6.1.2.2 RESTRAIN AND OPPORTINITIES

6.1.3 Hemophilia
6.1.4 Pulmonary embolism

6.1.4.1 DRIVER

6.2 Oncology diseases

6.2.1 Driver
6.2.2 Opportunities and restraints
6.2.3 Lungs cancer
6.2.4 Breast cancer
6.2.5 Cervical cancer
6.2.6 Colorectal cancer
6.2.7 Prostate cancer
6.2.8 Leukaemia

6.3 Chronic and autoimmune diseases

6.3.1 Diabetes

6.3.1.1 Drivers

6.3.2 Neutropenia
6.3.3 Multiple sclerosis

6.3.3.1 Drivers
6.3.3.2 Restraints and opportunities

6.3.4 Cystic Fibrosis
6.3.5 Rheumatoid arthritis (RA)

6.3.5.1 Drivers
6.3.5.2 Restraints

6.3.6 Acromegaly

6.3.6.1 drivers

6.3.7 Leprosy

6.4 Growth hormone deficiency

6.4.1 Drivers

6.5 Others

6.5.1 Gaucher disease
6.5.2 Osteoporosis

Chapter: 7 GLOBAL MARKET BY SERVICES

7.1 Contract Research and Manufacturing Services

7.1.1 Drivers
7.1.2 Restraints & Opportunities

7.2 Clinical trials

7.2.1 Drivers & Restraints
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III

Chapter: 8 GLOBAL BIOSIMILARS MARKET BY GEOGRAPHY

8.1 North America

8.1.1 Key market trends
8.1.2 Key growth factors and opportunities
8.1.3 Market size & forecast

8.2 Europe

8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size & forecast

8.3 Asia-Pacific

8.3.1 Key market trends

8.3.1.1 India

8.3.1.1.1 COMPETITIVE SCENARIO

8.3.1.2 China

8.3.1.2.1 COMPETITIVE SCENARIO

8.3.1.3 Australia

8.3.1.3.1 COMPETITIVE SCENARIO

8.3.2 Key growth factors and opporunities
8.3.3 Market size & forecast

8.4 LAMEA

8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size & forecast

Chapter: 9 KEY PRODUCTS AND RECENT ACTIVITIES

9.1 US

9.1.1 Hospira

9.1.1.1 Recent Activities

9.2 Europe

9.2.1 Stada Arzneimittel AG

9.2.1.1 Recent Activities

9.2.2 Hexal AG
9.2.3 Ratiopharm GmbH
9.2.4 Bioton

9.2.4.1 Recent Activities

9.2.5 Sandoz GmbH

9.2.5.1 Recent Activities

9.3 India

9.3.1 Dr.Reddy's Labs (DRL)

9.3.1.1 Recent Activities

9.3.2 Intas Pharmaceuticals Ltd.

9.3.2.1 Recent Activities

9.3.3 Wockhardt Limited

9.3.3.1 Recent Activities

9.3.4 Biocon Limited

9.3.4.1 Recent Activities

9.3.5 Shantha Biotechnics Limited

9.3.5.1 Recent Activities

9.3.6 Reliance Life Sciences

9.4 Korea

9.4.1 Dong-A Pharmaceutical Co., Ltd

9.4.1.1 Recent Activities

9.4.2 LG Life Sciences

9.4.2.1 Recent Activities

9.4.3 Celltrion Pharm, Inc.

9.4.3.1 Recent Activities

9.5 Others

9.5.1 Teva Pharmaceutical Industries Ltd.

9.5.1.1 Recent Activities

Chapter: 10 COMPANY PROFILES

10.1 Novartis (Sandoz)

10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segment overview
10.1.4 Business performance
10.1.5 Key strategies

10.1.5.1 Primary Strategies: Clinical Trials
10.1.5.2 secondary Strategies: approval

10.1.6 SWOT analysis

10.2 Synthon Pharmaceuticals, Inc.

10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segment overview
10.2.4 Key strategies

10.2.4.1 Primary Strategies: agreement
10.2.4.2 secondary Strategies: clinical trials

10.2.5 SWOT analysis

10.3 Teva Pharmaceutical Industries Ltd.

10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Operating business segment overview
10.3.4 Business performance
10.3.5 Key strategies

10.3.5.1 Primary Strategies: approval
10.3.5.2 secondary Strategies: clinical trials

10.3.6 SWOT analysis

10.4 LG Life Sciences

10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segment overview
10.4.4 Business performance
10.4.5 Key strategies

10.4.5.1 Primary Strategies: Collaboration

10.4.6 SWOT analysis

10.5 Celltrion

10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segment overview
10.5.4 Business Performance
10.5.5 Key strategies

10.5.5.1 Primary Strategies: approval

10.5.6 SWOT analysis

10.6 Biocon

10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segment overview
10.6.4 Business Performance
10.6.5 Key strategies

10.6.5.1 Primary Strategy: product launch
10.6.5.2 secondary Strategy: clinical trial

10.6.6 SWOT analysis

10.7 Hospira

10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segment overview
10.7.4 Business performance
10.7.5 Key strategies

10.7.5.1 Primary Strategies: approval
10.7.5.2 secondary Strategies: clinical trials

10.7.6 SWOT analysis

10.8 Merck Serono (Merck Group)

10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segment overview
10.8.4 Business performance
10.8.5 Key strategies

10.8.5.1 Primary Strategies: partnership and product launch

10.8.6 SWOT analysis

10.9 Biogen idec Inc.

10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segment overview
10.9.4 Business performance
10.9.5 Key strategies

10.9.5.1 Primary Strategies: agreement and joint venture

10.9.6 SWOT analysis

10.10 Genentech (Roche Group)

10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segment overview
10.10.4 Key strategies

10.10.4.1 Primary Strategies: Investment and license

10.10.5 SWOT analysis

LIST OF FIGURES

FIG. 1 TOP FACTORS IMPACTING BIOSIMILARS MARKET (2014-2020)
FIG. 2 TOP WINING STRATEGIES FOR BIOSIMILARS MARKET DURING (2010-2015)
FIG. 3 TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENTS (2010-2015)
FIG. 4 TOP INVESTMENT POCKETS OF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET PRODUCTS, 2014-2020
FIG. 5 KEY ACHIEVEMENTS FOR BIOSIMILAR REGULATORS (2010)
FIG. 6 REGULATORY FRAMEWORK FOR BIOSIMILAR PRODUCTS IN CHINA
FIG. 7 PORTERS FIVE FORCE ANALYSIS OF BIOSIMILARS MARKET
FIG. 8 VALUE CHAIN ANALYSIS OF BIOSIMILARS MARKET
FIG. 9 IMPACT ANALYSIS OF STAKEHOLDERS INVOLVED IN PRIMARY ACTIVITIES (2014-2020)
FIG. 10 MARKET SHARE ANALYSIS OF BIOSIMILARS MARKET (2014)
FIG. 11 IMPACT ANALYSIS OF PRODUCT MARKET SEGMENTS (2014, 2020-2025)
FIG. 12 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
FIG. 13 IMPACT ANALYSIS OF APPLICATION MARKET SEGMENTS (2014-2020-2025)
FIG. 14 IMPACT OF REGULATION ON VARIOUS GEOGRAPHIES, 2012
FIG. 15 NET REVENUE GENERATION BY GEOGRAPHY (2013)
FIG. 16 NET REVENUE GENERATION BY BUSINESSES (2013)
FIG. 17 SWOT ANALYSIS OF NOVARTIS (SANDOZ)
FIG. 18 SWOT ANALYSIS OF SYNTHON PHARMACEUTICALS
FIG. 19 NET REVENUE GENERATION BY GEOGRAPHY (2013)
FIG. 20 NET REVENUE GENERATION BY BUSINESSES (2013)
FIG. 21 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIG. 22 NET REVENUE GENERATION (2011-2013)
FIG. 23 SWOT ANALYSIS OF LG LIFE SCIENCES
FIG. 24 NET PROFIT DURING 2011-2013
FIG. 25 SWOT ANALYSIS OF CELLTRION
FIG. 26 REVENUE GENERATED BY BUSINESS UNITS (2013)
FIG. 27 SWOT ANALYSIS OF BIOCON
FIG. 28 NET SALES BY GEOGRAPHY (2013)
FIG. 29 NET SALES BY BUSINESS UNITS (2013)
FIG. 30 SWOT ANALYSIS OF HOSPIRA
FIG. 31 NET SALES BY GEOGRAPHY (2013)
FIG. 32 NET SALES BY BUSINESS UNITS (2013)
FIG. 33 SWOT ANALYSIS OF MERCK SERONO
FIG. 34 NET SALES BY GEOGRAPHY (2013)
FIG. 35 NET SALES BY BUSINESS UNITS (2013)
FIG. 36 SWOT ANALYSIS OF BIOGEN IDEC INC.
FIG. 37 SWOT ANALYSIS OF GENENTECH

LIST OF TABLES

TABLE 1 BIOSIMILARS MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 BIOSIMILARS RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 BIOSIMILARS DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 BIOSIMILARS GUIDELINES ADOPTED BY REGIONS
TABLE 5 COMPARISON OF BIOSIMILAR MEDICINE GUIDELINES BY GEOGRAPHY (2013)
TABLE 6 BIOSIMILARS DEVELOPMENT 2013 (LATIN AMERICA)
TABLE 7 OFF GOING PATENTS 2013-2016
TABLE 8 PREVALENCE OF TOP TWO CHRONIC DISEASES (2013)
TABLE 9 BIOSIMILAR DEVELOPMENT STATUS (2013)
TABLE 10 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2014-2020 ($MILLION)
TABLE 11 PATENTS STATUS FOR THE HUMAN GROWTH HORMONE (BIOLOGICS)
TABLE 12 PATENT EXPIRATION STATUS FOR HUMAN GROWTH HORMONE DURING 2014-2020 (BIOLOGICS)
TABLE 13 GLOBAL HGH BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)
TABLE 14 PATENTS APPROVED FOR INSULIN (BIOLOGICS)
TABLE 15 GLOBAL INSULIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)
TABLE 16 PATENTS APPROVED FOR INTERFERON (BIOLOGICS)
TABLE 17 PATENT EXPIRATION STATUS FOR INTERFERON DURING, 2014-2020 (BIOLOGICS)
TABLE 18 GLOBAL INTERFERON BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 19 PATENT EXPIRATION STATUS FOR G-CSF BIOSIMILARS DURING, 2014-2020 (BIOLOGICS)
TABLE 20 GLOBAL G-CSF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 21 PATENTS STATUS FOR ERYTHROPOIETIN (BIOLOGICS)
TABLE 22 PATENT EXPIRATION STATUS FOR ERYTHROPOIETIN DURING 2014-2020 (BIOLOGICS)
TABLE 23 GLOBAL ERYTHROPOIETIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 24 DRUG PATENT EXPIRATION FOR MONOCLONAL ANTIBODIES (BIOLOGICS)
TABLE 25 PATENT EXPIRATION STATUS FOR MONOCLONAL ANTIBODIES DURING, 2014-2020 (BIOLOGICS)
TABLE 26 GLOBAL MAB BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 27 GLOBAL PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014 -2020 ($MILLION)
TABLE 28 HIRUDIN BIOSIMILAR CANDIDATE STATUS
TABLE 29 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 30 GLOBAL BLOOD DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 31 GLOBAL ONCOLOGY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 32 GLOBAL CHRONIC AND AUTOIMMUNE DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 33 GLOBAL GROWTH HORMONE DEFICIENCY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 34 GLOBAL OTHER DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 35 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 36 NORTH AMERICA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATION, 2014-2020 ($MILLION)
TABLE 37 BIOSIMILARS COMMERCIALLY AVAILABLE IN EUROPEAN UNION
TABLE 38 EUROPE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 39 ASIA-PACIFIC BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 40 LAMEA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Biosimilars Market- Global Opportunity Analysis and Industry Forecast, 2014-2020

  • Online Only
  • $4176
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo